移植物的选择与前交叉韧带翻修重建6年结局的关联:MARS队列研究
该前瞻性队列研究纳入1234例前交叉韧带翻修重建患者,由83名术者在52个中心实施,随访至6年。结果显示,与BTB同种异体移植物相比,BTB自体移植物与更高的Marx活动评分和更低的再断裂风险相关;自体移植物与更少的再手术相关。
要点
- BTB自体移植物翻修后6年活动水平高于BTB同种异体移植物(OR 1.92,95%CI 1.25-2.94)。
- BTB自体移植物较BTB同种异体移植物再断裂风险低4.2倍(95%CI 1.56-11.27)。
- 自体移植物较同种异体移植物6年内再手术更少(OR 0.56,95%CI 0.36-0.87)。
核心结论
- BTB和软组织自体移植物较BTB同种异体移植物降低移植物再断裂风险。
- BTB自体移植物较BTB同种异体移植物在翻修重建后6年活动水平更高。
- 术者和患者在选择翻修ACL重建移植物时应考虑这些信息。
研究设计与样本
- 前瞻性队列研究,证据等级2级。
- 83名术者在52个中心前瞻性纳入翻修手术患者。
- 共纳入1234例患者,其中716例(58%)为男性。
- 809例(66%)获得问卷和电话随访,另128例仅电话随访,总随访949例(77%)。
主要发现
- BTB自体移植物组6年再断裂率3.5%(16/455),同种异体移植物组8.4%(37/441)。
- BTB自体移植物与软组织自体移植物(P=0.87)或软组织同种异体移植物(P=0.36)再断裂率无显著差异。
关键数值与推荐
- BTB自体移植物翻修后6年Marx活动评分高于BTB同种异体移植物(OR 1.92;95%CI 1.25-2.94)。
- 6年随访总再断裂率5.8%(55/949)。
临床怎么用
- 翻修ACL重建时,优先考虑自体移植物(尤其是BTB)以降低再断裂和再手术风险。
- 与患者沟通移植物选择时,应告知BTB自体移植物较BTB同种异体移植物在活动水平和再断裂方面的优势。
局限性
- 随访率有限,949例(77%)获得随访,其中128例仅电话随访。
- 移植物选择非随机,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although graft choice may be limited in the revision setting based on previously used grafts, most surgeons believe that graft choice for anterior cruciate ligament (ACL) reconstruction is an important factor related to outcome. HYPOTHESIS: In the ACL revision setting, there would be no difference between autograft and allograft in rerupture rate and patient-reported outcomes (PROs) at 6-year follow-up. STUDY DESIGN: Cohort study; Level of evidence, 2. METHODS: Patients who had revision surgery were identified and prospectively enrolled in this cohort study by 83 surgeons over 52 sites. Data collected included baseline characteristics, surgical technique and pathology, and a series of validated PRO measures. Patients were followed up at 6 years and asked to complete the identical set of PRO instruments. Incidence of additional surgery and reoperation because of graft failure were also recorded. Multivariable regression models were used to determine the predictors (risk factors) of PROs, graft rerupture, and reoperation at 6 years after revision surgery. RESULTS: A total of 1234 patients including 716 (58%) men were enrolled. A total of 325 (26%) underwent revision using a bone-patellar tendon-bone (BTB) autograft; 251 (20%), soft tissue autograft; 289 (23%), BTB allograft; 302 (25%), soft tissue allograft; and 67 (5%), other graft. Questionnaires and telephone follow-up for subsequent surgery information were obtained for 809 (66%) patients, while telephone follow-up was only obtained for an additional 128 patients for the total follow-up on 949 (77%) patients. Graft choice was a significant predictor of 6-year Marx Activity Rating Scale scores (P = .024). Specifically, patients who received a BTB autograft for revision reconstruction had higher activity levels than did patients who received a BTB allograft (odds ratio [OR], 1.92; 95% CI, 1.25-2.94). Graft rerupture was reported in 5.8% (55/949) of patients by their 6-year follow-up: 3.5% (16/455) of patients with autografts and 8.4% (37/441) of patients with allografts. Use of a BTB autograft for revision resulted in patients being 4.2 times less likely to sustain a subsequent graft rupture than if a BTB allograft were utilized (P = .011; 95% CI, 1.56-11.27). No significant differences were found in graft rerupture rates between BTB autograft and soft tissue autografts (P = .87) or between BTB autografts and soft tissue allografts (P = .36). Use of an autograft was found to be a significant predictor of having fewer reoperations within 6 years compared with using an allograft (P = .010; OR, 0.56; 95% CI, 0.36-0.87). CONCLUSION: BTB and soft tissue autografts had a decreased risk in graft rerupture compared with BTB allografts. BTB autografts were associated with higher activity level than were BTB allografts at 6 years after revision reconstruction. Surgeons and patients should consider this information when choosing a graft for revision ACL reconstruction.
引用
- Wright RW, Huston LJ, Haas AK, et al. Association Between Graft Choice and 6-Year Outcomes of Revision Anterior Cruciate Ligament Reconstruction in the MARS Cohort. Am J Sports Med. 2021. PMID: 34260326. doi:10.1177/03635465211027170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。